Logo image of PCVX

VAXCYTE INC (PCVX) Stock Fundamental Analysis

NASDAQ:PCVX - Nasdaq - US92243G1085 - Common Stock - Currency: USD

79.74  -2.73 (-3.31%)

After market: 79.74 0 (0%)

Fundamental Rating

3

PCVX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. While PCVX has a great health rating, there are worries on its profitability. PCVX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year PCVX has reported negative net income.
PCVX had a negative operating cash flow in the past year.
PCVX had negative earnings in each of the past 5 years.
PCVX had a negative operating cash flow in each of the past 5 years.
PCVX Yearly Net Income VS EBIT VS OCF VS FCFPCVX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -100M -200M -300M -400M

1.2 Ratios

PCVX has a better Return On Assets (-14.26%) than 84.01% of its industry peers.
Looking at the Return On Equity, with a value of -14.85%, PCVX belongs to the top of the industry, outperforming 89.34% of the companies in the same industry.
Industry RankSector Rank
ROA -14.26%
ROE -14.85%
ROIC N/A
ROA(3y)-27.21%
ROA(5y)-36.17%
ROE(3y)-30.37%
ROE(5y)-42.03%
ROIC(3y)N/A
ROIC(5y)N/A
PCVX Yearly ROA, ROE, ROICPCVX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80

1.3 Margins

PCVX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PCVX Yearly Profit, Operating, Gross MarginsPCVX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, PCVX has more shares outstanding
Compared to 5 years ago, PCVX has more shares outstanding
PCVX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PCVX Yearly Shares OutstandingPCVX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
PCVX Yearly Total Debt VS Total AssetsPCVX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 500M 1B

2.2 Solvency

PCVX has an Altman-Z score of 43.12. This indicates that PCVX is financially healthy and has little risk of bankruptcy at the moment.
PCVX's Altman-Z score of 43.12 is amongst the best of the industry. PCVX outperforms 97.51% of its industry peers.
There is no outstanding debt for PCVX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 43.12
ROIC/WACCN/A
WACCN/A
PCVX Yearly LT Debt VS Equity VS FCFPCVX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 500M 1B

2.3 Liquidity

PCVX has a Current Ratio of 17.88. This indicates that PCVX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 17.88, PCVX belongs to the top of the industry, outperforming 92.90% of the companies in the same industry.
A Quick Ratio of 17.88 indicates that PCVX has no problem at all paying its short term obligations.
PCVX's Quick ratio of 17.88 is amongst the best of the industry. PCVX outperforms 92.90% of its industry peers.
Industry RankSector Rank
Current Ratio 17.88
Quick Ratio 17.88
PCVX Yearly Current Assets VS Current LiabilitesPCVX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

More info and screens

0

3. Growth

3.1 Past

PCVX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -38.14%.
EPS 1Y (TTM)-38.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.79%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, PCVX will show a small growth in Earnings Per Share. The EPS will grow by 1.29% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y0.61%
EPS Next 2Y-7.88%
EPS Next 3Y-8.98%
EPS Next 5Y1.29%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PCVX Yearly Revenue VS EstimatesPCVX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B 5B
PCVX Yearly EPS VS EstimatesPCVX Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 10 15 20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PCVX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PCVX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PCVX Price Earnings VS Forward Price EarningsPCVX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PCVX Per share dataPCVX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20

4.3 Compensation for Growth

A cheap valuation may be justified as PCVX's earnings are expected to decrease with -8.98% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-7.88%
EPS Next 3Y-8.98%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PCVX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VAXCYTE INC

NASDAQ:PCVX (2/21/2025, 8:00:00 PM)

After market: 79.74 0 (0%)

79.74

-2.73 (-3.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2024-11-05/amc
Earnings (Next)02-25 2025-02-25/amc
Inst Owners112.55%
Inst Owner Change3.77%
Ins Owners0.49%
Ins Owner Change-1.48%
Market Cap9.94B
Analysts87.06
Price Target152.89 (91.74%)
Short Float %11.21%
Short Ratio12.44
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.41%
Min EPS beat(2)-9.49%
Max EPS beat(2)28.3%
EPS beat(4)2
Avg EPS beat(4)-4.73%
Min EPS beat(4)-66.45%
Max EPS beat(4)28.7%
EPS beat(8)4
Avg EPS beat(8)-1.03%
EPS beat(12)5
Avg EPS beat(12)-2.79%
EPS beat(16)9
Avg EPS beat(16)1.97%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0.4%
EPS NQ rev (1m)2.05%
EPS NQ rev (3m)2.55%
EPS NY rev (1m)1.03%
EPS NY rev (3m)1.23%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.91
P/tB 2.91
EV/EBITDA N/A
EPS(TTM)-4.6
EYN/A
EPS(NY)-4.81
Fwd EYN/A
FCF(TTM)-4.94
FCFYN/A
OCF(TTM)-3.77
OCFYN/A
SpS0
BVpS27.42
TBVpS27.42
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.26%
ROE -14.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.21%
ROA(5y)-36.17%
ROE(3y)-30.37%
ROE(5y)-42.03%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2909.43%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.88
Quick Ratio 17.88
Altman-Z 43.12
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)913.97%
Cap/Depr(5y)584.35%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-38.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.79%
EPS Next Y0.61%
EPS Next 2Y-7.88%
EPS Next 3Y-8.98%
EPS Next 5Y1.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-57.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-40.55%
EBIT Next 3Y-26.5%
EBIT Next 5YN/A
FCF growth 1Y-279.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-200.4%
OCF growth 3YN/A
OCF growth 5YN/A